Citigroup Reiterates Neutral Rating on Bio-Rad Laboratories, Inc. (BIO)

Market Context

Bio-Rad Laboratories, Inc. operates in the Healthcare sector. The stock currently trades at $347.86 with a market capitalization of $8.5B. The stock has gained 17.0% over the past 52 weeks.

Analyst coverage from Citigroup provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Bio-Rad Laboratories, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Bio-Rad Laboratories, Inc.

Among the 10 most recent ratings: 4 Buy, 6 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 05, 2026	Wells Fargo	Equal-Weight	N/A
Aug 05, 2026	RBC Capital	Outperform	N/A
Aug 05, 2026	Citigroup	Neutral	N/A
May 15, 2026	RBC Capital	Outperform	N/A
May 01, 2026	Wells Fargo	Equal-Weight	N/A

Related Tools: Analyst Ratings Dashboard | View BIO Stock Page